German center subanalysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease

Journal of Endovascular Therapy

Volumn 23, Issue 3, 2016, Pages 409-416

  Scheinert, Dierk ^a   Schmidt, Andrej ^a   Zeller, Thomas ^b   Müller Hülsbeck, Stefan ^c   Sixt, Sebastian ^d   Schröder, Henrik ^e   Weiss, Norbert ^f   Ketelsen, Dominik ^g   Ricke, Jens ^h   Steiner, Sabine ^a   Rosenfield, Kenneth ⁱ  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^c Diakonissenanstalt zu Flensburg ^*  (Germany)

^d UNIVERSITY HEART CENTER HAMBURG   (Germany)

^e Jewish Hospital   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h OTTO VON GUERICKE UNIVERSITY   (Germany)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angioplasty; Drug coated balloon; Drug eluting balloon; Geography; Paclitaxel; Peripheral vascular disease; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

AGED; AMPUTATION; ANGIOPLASTY; ARTICLE; BALLOON; CALCIFICATION; CATHETER; CLAUDICATION; CONTROLLED STUDY; DRUG COATING; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; ECHOGRAPHY; FEMALE; FEMOROPOPLITEAL BYPASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; SIX MINUTE WALK TEST; STENOSIS; THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICES; DIAGNOSTIC IMAGING; FEMORAL ARTERY; GERMANY; INTERMITTENT CLAUDICATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RECURRENT DISEASE; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME FACTOR; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

AGED; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; FEMALE; FEMORAL ARTERY; GERMANY; HUMANS; INTERMITTENT CLAUDICATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; RECURRENCE; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 85012914021     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602816644592     Document Type: Article

References (15)

1. Levy PJ. Epidemiology and pathophysiology of peripheral arterial disease. Clin Cornerstone. 2002;4:1-15.
2. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910-919.
3. Klein AJ, Chen SJ, Messenger JC, et al. Quantitative assessment of the conformational change in the femoropopliteal artery with leg movement. Catheter Cardiovasc Interv. 2009;74:787-798.
4. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
5. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504.
6. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315.
7. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10-19.
8. Tepe G, Schmitmeier S, Speck U, et al. Advances on drug-coated balloons. J Cardiovasc Surg (Torino). 2010;51:125-143.
9. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699.
10. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
11. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502.
12. Rosenfield K, Jaff MR, White CJ, et al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-153.
13. Yazdani SK, Pacheco E, Nakano M, et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. 2014;83:132-140.
14. Ducrocq G, Bhatt DL, Labreuche J, et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. Eur J Prev Cardiol. 2014;21:1509-1516.
15. Jaff MR, Rosenfield K, Scheinert D, et al. Drug-coated balloons to improve femoropopliteal artery patency: rationale and design of the LEVANT 2 trial. Am Heart J. 2015;169:479-485.